Metformin is a medication commonly used to manage blood sugar levels in people with type 2 diabetes. In this clinical trial, it is being used to study its effects on breast cancer tissue, specifically looking at changes in cancer cell growth markers before and after treatment. The trial aims to see if Metformin, when combined with a specific eating pattern, can influence cancer cell activity.

Time Restricted Eating involves limiting the hours during which food is consumed each day. In this trial, participants are asked to fast for at least 16 hours overnight. This approach is being tested to see if it can enhance the effects of Metformin on breast cancer cells, potentially slowing down their growth or reducing their activity.

Invasive Breast Cancer – This type of breast cancer occurs when cancer cells spread beyond the ducts or lobules into the surrounding breast tissue. It can be classified based on hormone receptor status, such as estrogen receptor-positive (ER+) or progesterone receptor-positive (PgR+). The disease progresses as cancer cells invade nearby tissues and potentially spread to other parts of the body through the lymphatic system or bloodstream. Early stages may not cause noticeable symptoms, but as it advances, it can lead to changes in breast shape, size, or skin texture. Regular monitoring and medical evaluations are crucial for understanding its progression.

Ductal Carcinoma In Situ (DCIS) – This is a non-invasive form of breast cancer where abnormal cells are found in the lining of a breast duct but have not spread outside the duct. It is considered the earliest form of breast cancer and is sometimes referred to as stage 0. DCIS itself does not typically cause symptoms, but it can be detected through mammograms as microcalcifications. If left untreated, it may progress to invasive breast cancer, where cancer cells break through the duct walls and invade surrounding tissue. Monitoring and early detection are key to managing this condition effectively.